S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:MESOMesoblast Stock Price, Forecast & News

$11.81
+0.48 (+4.24 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.00
Now: $11.81
$11.85
50-Day Range
$10.91
MA: $12.86
$17.42
52-Week Range
$3.12
Now: $11.81
$20.57
Volume1.13 million shs
Average Volume668,015 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.51
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More
Mesoblast logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.72 million
Book Value$4.82 per share

Profitability

Net Income$-89,800,000.00
Net Margins-197.65%

Miscellaneous

Employees81
Market Cap$1.38 billion
Next Earnings Date9/3/2020 (Estimated)
OptionableOptionable
$11.81
+0.48 (+4.24 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mesoblast (NASDAQ:MESO) Frequently Asked Questions

How has Mesoblast's stock price been impacted by Coronavirus?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MESO shares have increased by 96.0% and is now trading at $11.81.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mesoblast?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mesoblast
.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020.
View our earnings forecast for Mesoblast
.

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) released its earnings results on Wednesday, May, 27th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The firm earned $12.20 million during the quarter, compared to analysts' expectations of $9.38 million. Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%.
View Mesoblast's earnings history
.

What price target have analysts set for MESO?

7 brokers have issued 1 year price targets for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they expect Mesoblast's share price to reach $15.04 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price.
View analysts' price targets for Mesoblast
.

Has Mesoblast been receiving favorable news coverage?

News stories about MESO stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mesoblast earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Mesoblast
.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,190,000 shares, an increase of 26.8% from the June 15th total of 938,400 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 1.0 days.
View Mesoblast's Short Interest
.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Exelixis (EXEL), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Novavax (NVAX), TherapeuticsMD (TXMD), AbbVie (ABBV) and Corbus Pharmaceuticals (CRBP).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (1.19%), Penbrook Management LLC (0.19%), Goldman Sachs Group Inc. (0.17%), Princeton Capital Management LLC (0.12%), Sit Investment Associates Inc. (0.03%) and Wilbanks Smith & Thomas Asset Management LLC (0.02%).

Which institutional investors are selling Mesoblast stock?

MESO stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Wilbanks Smith & Thomas Asset Management LLC, and Penbrook Management LLC.

Which institutional investors are buying Mesoblast stock?

MESO stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Sit Investment Associates Inc., Princeton Capital Management LLC, SG Americas Securities LLC, UBS Group AG, and Bank of New York Mellon Corp.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $11.81.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $1.38 billion and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.